1 U.S. lawmaker has disclosed 1 Ultragenyx Pharmaceutical Inc. - trade under the STOCK Act — 1 buy and 0 sells in 2025. Congress has been net buyers of RARE, and their disclosed buys are down 3.5% versus the latest close.
*Notional-weighted price return on lawmakers' disclosed buys of RARE, marked to the latest close — per-share (share counts aren't disclosed).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2025-07-15 | Gilbert Cisneros | BUY | $1K–$15K | $27.20 | $26.26 2026-08-27 | -3.5% |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
1 member of the U.S. House and Senate has disclosed Ultragenyx Pharmaceutical Inc. - transactions under the STOCK Act — 1 purchase and 0 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a RARE purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Notional-weighted, lawmakers' disclosed RARE buys are down 3.5% versus the latest close of $26.26. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded RARE and how it performed.